Using AI-Powered Diagnostics to Identify Optimal Therapies for Prostate Cancer with Andre Esteva Artera
Andre Esteva is the CEO and Co-Founder of Artera, a company focused on improving prostate cancer diagnostics. The company use [...]
Predicting Cancer Treatment Response
One of the greatest fantasies in medicine is to one day be able to offer any patient a therapy perfectly adapted to their pro [...]
How AI personalizes cancer therapy
From images of patients' digitized pathology, AI gets a view of cells of the tumor for recommended therapy and long- term pro [...]
Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO
In this latest episode of Exploring Artificial Intelligence in Oncology, Fellows Forum member Dr. Waqas Haque sits down with [...]
MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer – Phuoc Tran & Tim Showalter
Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in..
AI’s Role in Predicting Cancer Treatment Outcomes
In this episode of the Target Cancer Podcast, Dr. Sanjay Juneja talks with Dr. Tim Showalter, CMO at Artera, about using AI t [...]
AI-Powered Prostate Cancer Risk Assessment Tool Validated for Low-risk and Active Surveillance – Andre Esteva
Alicia Morgans interviews Andre Esteva about ArteraAI's expanded prostate cancer test, now validated for low-risk and active [...]
MMAI Model Risk Stratification for NCCN Guidelines for Low, Intermediate, and High-Risk Prostate Cancer – Neal Shore, Daniel Spratt, & Alicia Morgans
Zach Klaassen hosts a multidisciplinary roundtable discussing the NCCN Prostate Cancer Guidelines with a focus on the ArteraA [...]
Predicting Response to Hormone Therapy in Prostate Cancer With a Post-Prostatectomy MMAI Model – UroToday
Zach Klaassen discusses with Todd Morgan about innovative post-prostatectomy biomarkers. Dr. Morgan presents findings on a ne [...]